Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Shoji, Takakura"'
Autor:
Toshiyuki Takasu, Shoji Takakura
Publikováno v:
Life Sciences. 230:19-27
Aims We investigated the effect of the selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin on cardiac dysfunction and histopathology in a non-diabetic rat model of cardiomyopathy. Main methods Ipragliflozin was mixed wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42b173e47ea787d9d8ec0128a66af885
https://doi.org/10.1016/j.lfs.2019.05.051
https://doi.org/10.1016/j.lfs.2019.05.051
Publikováno v:
Biological and Pharmaceutical Bulletin. 42:507-511
Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes mellitus. To date, the only known in vitro pharmacological characteristic of ipragliflozin is its selectivity for SGLT2 over SGL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bb6ae5fb47bb0e0faf429b3fbea81e9
https://doi.org/10.1248/bpb.b18-00728
https://doi.org/10.1248/bpb.b18-00728
Autor:
Tatsuaki Morokata, Shoji Takakura, Hidehiko Fukahori, Koji Nakamura, Shinsuke Oshima, Jun Hirose, Yasuyuki Higashi, Takahisa Noto, Susumu Tsujimoto, Masashi Maeda, Kaori Hanaoka
Publikováno v:
Transplant Immunology. 52:32-39
We examined the benefit of a loading dose of tacrolimus on the production of donor-specific antibodies (DSA), occurrence of acute rejection (AR) episodes, graft survival, and histological evidence of antibody-mediated rejection (ABMR) after kidney tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa37e6e8fa6841bb7a7579b11077d276
https://doi.org/10.1016/j.trim.2018.10.004
https://doi.org/10.1016/j.trim.2018.10.004
Autor:
Toshiyuki Takasu, Shoji Takakura
Publikováno v:
Clinical and Experimental Pharmacology and Physiology. 46:266-273
The first dose of a sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor induces osmotic diuresis and can thereby affect cardiovascular activity in hyperglycemic patients. We aimed to determine whether the first dose of the selective SGLT2 inhi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b67ea3412d9ef51711e44c6d6df629f5
https://doi.org/10.1111/1440-1681.13053
https://doi.org/10.1111/1440-1681.13053
Autor:
Toshiyuki Takasu, Yuka Hayashizaki, Shoji Takakura, Nobuaki Amino, Jiro Hirosumi, Eiji Kurosaki, Hideaki Minoura
Publikováno v:
Biological & Pharmaceutical Bulletin. 40:675-680
Sodium glucose cotransporter 2 (SGLT2) inhibitors improve hyperglycemia in patients with type 2 diabetes mellitus (T2DM) by increasing urinary glucose excretion. In addition to their antihyperglycemic effect, SGLT2 inhibitors also reduce body weight
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d23e49d79b6cb9f699e377a545ed566
https://doi.org/10.1248/bpb.b16-00964
https://doi.org/10.1248/bpb.b16-00964
Autor:
Shoji Takakura, Toshiyuki Takasu
Publikováno v:
Biologicalpharmaceutical bulletin. 42(10)
Recent clinical studies indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors exhibit a renoprotective effect. While studies at the single nephron level suggest that direct effects of SGLT2 inhibitors on renal hemodynamics may be a possible
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f9a64e40d43a3f59c6f8487420922df
https://pubmed.ncbi.nlm.nih.gov/31582658
https://pubmed.ncbi.nlm.nih.gov/31582658
Publikováno v:
Biologicalpharmaceutical bulletin. 42(3)
Ipragliflozin, a selective sodium glucose cotransporter 2 (SGLT2) inhibitor, is used for the treatment of type 2 diabetes mellitus. To date, the only known in vitro pharmacological characteristic of ipragliflozin is its selectivity for SGLT2 over SGL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fe7fd5bbd6488c7d37931db3391ad38e
https://pubmed.ncbi.nlm.nih.gov/30828082
https://pubmed.ncbi.nlm.nih.gov/30828082
Publikováno v:
Life Sciences. 147:125-131
Aims We investigated the effect of the selective sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin on the simultaneous progression of diabetic microvascular complications of retinopathy, nephropathy and neuropathy in individual Spontan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad2459fec1f6f7a58b7a8e2a95cc1548
https://doi.org/10.1016/j.lfs.2016.01.042
https://doi.org/10.1016/j.lfs.2016.01.042
Publikováno v:
Folia Pharmacologica Japonica. 148:266-271
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfe995e28b6bf28e41c12996a09bd9ce
https://doi.org/10.1254/fpj.148.266
https://doi.org/10.1254/fpj.148.266
Autor:
Shoji Takakura, Toshiyuki Takasu
Publikováno v:
Biologicalpharmaceutical bulletin. 41(5)
Ipragliflozin is a selective sodium glucose cotransporter 2 (SGLT2) inhibitor that increases urinary glucose excretion and subsequently improves hyperglycemia in patients with type 2 diabetes mellitus (T2DM). To assess the beneficial effect of ipragl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6efaf764f243f0dc43fe775a270de196
https://pubmed.ncbi.nlm.nih.gov/29709913
https://pubmed.ncbi.nlm.nih.gov/29709913